High Efficacity of Theinterferon-Free Treatment in Patients with Viral C Liver Cirrhosis Child A

HIGH EFFICACITY OF THEINTERFERON-FREE TREATMENT IN PATIENTS WITH VIRAL C LIVER CIRRHOSIS CHILD A

Simona Bataga, Cristina Furnea, Imola Torok, Dan Georgescu, Anca Negovan, Marius Ciorba, Mariana Tilinca, MelaniaMacarie.

First Clinic of Gastroenterology, University of Medicine and Pharmacy, Targu-Mures

Chronic liver hepatitis and liver cirrhosis have still a high incidence: about 140 million people worldwide have hepatitis C, and about 9 million people have the infection in Europe.

Scope.

Aim of the study is to evaluate the interferon-free treatment, at the first group of patients with viral C liver cirrhosis Child A. In all the patients the treatment with VIEKIRAX® (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA® (dasabuvir tablets) and Ribavirin have been initiated for 12 weeks.

Material and methods.

A total of 79 patients (49 male, mean age 57.2 years) entered the treatment. 10(12,65) of the patients have variceal hemorrhage, ascites, but at the time of the treatment they were compensated and fit into Child A.From the patients only one had genotype 1a, all the rest were with genotype 1b. The most important side effects were: headache in 10 patients (12,65)%, joint pain 6 (7,59%), itching 6 (7,59%), high blood pressure 6 (7,59%), nausea 6 (7,59%) insomnia 4 (5.06%). Rare symptoms, anemia, loss of appetite, weight loss, diarrhea, pain in the spine, epistaxis, burning of the anus and lips. Laboratory: 36 (45,56%) of patients experienced elevations in total bilirubin, the highest value being 5 (wave normal <1.2). In 5 patients the administration of the ribavirin was discontinued,

One patient required hospitalization, developing anemia (Htc 24%) and received transfusion.

In all 79 patients under treatment the HCV-RNA was undetectable at the end of the treatment and at 12 weeks after.

Conclusion

The interferon–free treatment with Exviera and Viekirax is generally well tolerated, even when applied to patients with liver cirrhosis. 100% from the patients had SVR/12at the end of the treatment.

Cuvintecheie : interferon-free treatment, liver cirrhosis C, Viekirax-pax

EFICCITATEA INALTA A TRATAMENTULUI FARA INTERFERON LA PACIENTII CU CIROZA VIRALA C CLASA CHILD A

SimonaBataga, Cristina Furnea, ImolaTorok, Dan Georgescu, AncaNegovan, Marius Ciorba, Mariana Tilinca, MelaniaMacarie.

Clinica de Gastroenterologie I, UMF Targu-Mures

Hepatiacronicavirala C siciroza hepatica prezintainca o incidentacrescuta, aproximativ 140 de milioane de oameni au hepatitavirala C in lume, si in jur de 9 milioane de persoaneprezintainfectia in Europa.

Scop.

Scopullucrariiesteevaluareatratamentuluifara interferon, la primul lot de pacientii cu cirozavirala C Clasa Child A, in ClinicaGastroentrologie I Tg-Mures. La totipacientii s-a initiattratamentul cu VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablete) + EXVIERA® (dasabuvirtablete) siRibavirinatimp de 12 saptamani.

Material simetode.

Un numar de 79de pacienti (41 de sex masculin, varstamedie 57,2 ani) cu ciroza hepatica virala C clasa Child A au fostinclusi in tratament. 10(12,65)pacientii au avut in antecedente HDS, ligatura de varice, ascita, dar la momentulinitieriieraucompensatisi se incadrau in clasa Child A. Un singurpacient a prezentatgenotip 1a, la restul s-a evidentiat genotip 1b. Casiefectesecundare au predominat: cefaleela 10pacienti (12,65)%, dureriarticulare 6 (7,59%), mancarimi 6(7,59%),crestereatensiuniiarteriale 6(7,59%), greata 6(7,59%), insomnia 4 (5,06%). Simptomemai rare:anemie, inapetenta,scadereponderala, scaunediareice, dureri ale coloaneivertebrale, epistaxis, usturime la nivelulanusuluisi a buzelor. Laborator: 36(45,56%) dinpacienti au prezentatcresteri ale bilirubineitotale, ceamai mare valoarefiind, 5 (valnormala <1.2). La 5 pacienti s-a interrupt administrarearibavirinei.

O singurapacienta a necesitatspitalizare, dezvoltandanemie (Htc: 24%) si a necesitattransfuzie.

La toticei 79 de pacientiaflati in tratament,ARNVHC a fostnedetectabil la sfarsitultratamentuluisi la 12 saptamani, avand RVS.

Concluzii

Tratamentul cu ViekiraxsiExvieraeste in general bine tolerat, chiardaca se aplica la pacienti cu ciroza hepaticaclasa CHILD A. 100% din pacienti au prezentat RVS/12 laterminareatratamentului.

Cuvintecheie: tratamentinterferon-free, ciroza hepatica virala C, Viekirax-pax